BRPI0206432A2 - métodos para administrar dois ou mais agentes terapêuticos ativos e para tratar diabetes melito ou sintomas associados com diabetes melito em um humano e sistema de liberação espaçada de medicamento - Google Patents

métodos para administrar dois ou mais agentes terapêuticos ativos e para tratar diabetes melito ou sintomas associados com diabetes melito em um humano e sistema de liberação espaçada de medicamento

Info

Publication number
BRPI0206432A2
BRPI0206432A2 BRPI0206432A BR0206432A BRPI0206432A2 BR PI0206432 A2 BRPI0206432 A2 BR PI0206432A2 BR PI0206432 A BRPI0206432 A BR PI0206432A BR 0206432 A BR0206432 A BR 0206432A BR PI0206432 A2 BRPI0206432 A2 BR PI0206432A2
Authority
BR
Brazil
Prior art keywords
diabetes mellitus
spaced drug
drug delivery
administering
delivery system
Prior art date
Application number
BRPI0206432A
Other languages
English (en)
Inventor
Dilip Shantilal Shanghvi
Kirti Wardhaman Ganorkar
Nitin Bhalachandra Dharmadhikari
Satish C Khanna
Yashoraj Rupsinh Zala
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IN37MU2001 external-priority patent/IN191539B/en
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of BRPI0206432A2 publication Critical patent/BRPI0206432A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
BRPI0206432A 2001-01-12 2002-01-11 métodos para administrar dois ou mais agentes terapêuticos ativos e para tratar diabetes melito ou sintomas associados com diabetes melito em um humano e sistema de liberação espaçada de medicamento BRPI0206432A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN37MU2001 IN191539B (pt) 2001-01-12 2001-01-12
IN324MU2001 2001-04-10
IN325MU2001 2001-04-10
IN323MU2001 2001-04-10
IN326MU2001 2001-04-10
PCT/IN2002/000005 WO2002055009A1 (en) 2001-01-12 2002-01-11 Spaced drug delivery system

Publications (1)

Publication Number Publication Date
BRPI0206432A2 true BRPI0206432A2 (pt) 2016-10-25

Family

ID=27517736

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0206432A BRPI0206432A2 (pt) 2001-01-12 2002-01-11 métodos para administrar dois ou mais agentes terapêuticos ativos e para tratar diabetes melito ou sintomas associados com diabetes melito em um humano e sistema de liberação espaçada de medicamento

Country Status (9)

Country Link
US (2) US7964216B2 (pt)
EP (2) EP1738751B1 (pt)
JP (1) JP4633329B2 (pt)
AT (1) ATE508738T1 (pt)
BR (1) BRPI0206432A2 (pt)
CA (2) CA2434169C (pt)
MX (1) MXPA03006217A (pt)
PL (1) PL362687A1 (pt)
WO (1) WO2002055009A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040156900A1 (en) * 2001-04-10 2004-08-12 Shanghvi Dilip Shantilal Time pulsed release composition
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
PL376577A1 (pl) 2002-06-17 2006-01-09 Themis Laboratories Private Limited Wielowarstwowe tabletki zawierające tiazolidinedion i biguanidy oraz metody ich wytwarzania
AU2003281181A1 (en) * 2002-07-11 2004-02-02 Takeda Pharmaceutical Company Limited Process for producing coated preparation
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
WO2004067001A1 (ja) 2003-01-29 2004-08-12 Takeda Pharmaceutical Company Limited 被覆製剤の製造法
WO2004108067A2 (en) * 2003-04-03 2004-12-16 Sun Pharmaceutical Industries Limited Programmed drug delivery system
TWI339586B (en) 2003-10-31 2011-04-01 Takeda Chemical Industries Ltd Solid preparation comprising pioglitazone or salt thereof,glimpiride and polyoxyethylene sorbitan fatty acid ester
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
MXPA05009633A (es) * 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.
US8187633B2 (en) * 2005-11-03 2012-05-29 Sun Pharma Advanced Research Company Limited Controlled release coated tablets having prolonged gastric retention
WO2007131930A1 (en) * 2006-05-13 2007-11-22 Novo Nordisk A/S Tablet formulation comprising repaglinide and metformin
CA2672602C (en) 2006-12-18 2014-05-20 Electronic Dietary Foods Inc. Device for delivery of a substance
CA2677623C (en) * 2007-02-09 2015-04-07 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
MX2010001071A (es) * 2007-07-27 2010-03-09 Depomed Inc Formas de dosificacion retentivas gastricas pulsatiles.
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
WO2012094636A2 (en) 2011-01-07 2012-07-12 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
CN104349773A (zh) 2012-01-06 2015-02-11 埃尔舍利克斯治疗公司 用于治疗代谢性病症的组合物和方法
BR112014016808B1 (pt) 2012-01-06 2022-01-11 Anji Pharma (Us) Llc Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose
US10835495B2 (en) 2012-11-14 2020-11-17 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
EP2941245B1 (en) * 2013-01-05 2024-06-26 Anji Pharmaceuticals Inc. Delayed-release composition comprising biguanide
HUE066123T2 (hu) * 2013-06-13 2024-07-28 Akebia Therapeutics Inc Készítmények és módszerek anémia kezelésére
CN104621714B (zh) * 2014-12-04 2018-01-05 湖北中烟工业有限责任公司 一种提高脆性的烟用添加剂滴丸及其制备方法
CN110882261A (zh) * 2019-12-27 2020-03-17 无锡福祈制药有限公司 二甲双胍格列吡嗪制剂
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3247066A (en) 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
DE2021147A1 (de) * 1970-04-30 1971-11-11 Christian Brunnengraeber Chem Kapsel mit einer Fuellung von Pharmazeutika
DE2347531A1 (de) * 1973-09-21 1975-04-30 Hoechst Ag Arzneizubereitungen zur oralen diabetes-behandlung
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
ZA822995B (en) * 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
US4681583A (en) 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
JPS60241871A (ja) * 1984-05-16 1985-11-30 Ajinomoto Co Inc アスパルテ−ム含有崩壊錠剤の製造法
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
DE3629994A1 (de) 1986-09-03 1988-03-17 Weissenbacher Ernst Rainer Pro Vorrichtung zur medikamentenapplikation in koerperhoehlen bzw. auf koerperoberflaechen
US4874388A (en) * 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US4976967A (en) * 1987-08-03 1990-12-11 Merck & Co., Inc. Resin modulated drug delivery device for the delivery of HMG-CoA reductase inhibitor salts
US4891223A (en) * 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
US4990535A (en) 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
GB8913889D0 (en) * 1989-06-16 1989-08-02 May & Baker Ltd New compositions of matter
EP0408496A3 (en) 1989-07-12 1992-07-01 Ciba-Geigy Ag Solid dosage form for pharmaceutical substances
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5229131A (en) 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5474784A (en) * 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
US5226902A (en) * 1991-07-30 1993-07-13 University Of Utah Pulsatile drug delivery device using stimuli sensitive hydrogel
PT100944B (pt) * 1991-10-10 2000-02-29 Alza Corp Dispositivo para o fornecimento osmotico de farmacos com paredes de materiais hidrofobicos
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
RU2127586C1 (ru) 1991-12-27 1999-03-20 Мерк Энд Ко., Инк. Устройство доставки лекарственного препарата, способ получения устройства
US5209746A (en) * 1992-02-18 1993-05-11 Alza Corporation Osmotically driven delivery devices with pulsatile effect
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
DE19718012C1 (de) * 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6004582A (en) * 1997-05-30 1999-12-21 Laboratorios Phoenix U.S.A, Inc. Multi-layered osmotic device
ES2159184T3 (es) 1997-06-13 2001-09-16 Novo Nordisk As Nueva posologia para la dmni.
EP1671637A3 (en) 1997-06-18 2007-12-19 SmithKline Beecham P.L.C. Treatment of diabetes with thiazolidinedione and sulphonylurea
TR199903057T2 (xx) 1997-06-18 2000-04-21 Smithkline Beecham Plc Diabetin tiazolidinedion ve metformin ile tedavisi.
GB9715298D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715295D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
DE69814122T2 (de) 1997-10-09 2004-03-18 Dexcel Pharma Technologies Ltd. Darreichungsform zur verzögerten, vollständigen wirkstoffabgabe im verdauungstrakt
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
CA2312990C (en) 1997-12-08 2008-04-29 Bristol-Myers Squibb Company Novel salts of metformin and method
WO1999047128A1 (en) * 1998-03-19 1999-09-23 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
DE69818444T2 (de) * 1998-07-15 2004-05-06 Merck Santé Tabletten enthaltend eine Kombination von Glibenclamid und Metformin
US6099862A (en) 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
WO2000025757A1 (en) 1998-10-29 2000-05-11 Merck & Co., Inc. Sustained release delivery of highly water-soluble compounds
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
WO2000028989A1 (en) * 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
DE19860698A1 (de) * 1998-12-30 2000-07-06 Hexal Ag Neue pharmazeutische Zusammensetzung
WO2000059481A1 (en) * 1999-04-06 2000-10-12 Pharmaquest Ltd. PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
JP2003504415A (ja) * 1999-07-20 2003-02-04 メルク エンド カムパニー インコーポレーテッド 持続放出性薬物分散剤輸送装置
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
EP1095650A1 (en) 1999-10-29 2001-05-02 Universiteit Leiden Double phase time-controlled release system
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
US6376682B1 (en) * 2000-02-01 2002-04-23 Takama System, Ltd. Compound with α-glucosidase inhibiting action and method for producing the same
MXPA02007254A (es) * 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US20030086972A1 (en) 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
GB0025208D0 (en) * 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
US20040156900A1 (en) * 2001-04-10 2004-08-12 Shanghvi Dilip Shantilal Time pulsed release composition
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
WO2004108067A2 (en) * 2003-04-03 2004-12-16 Sun Pharmaceutical Industries Limited Programmed drug delivery system

Also Published As

Publication number Publication date
EP1738751A3 (en) 2007-01-17
US20110250271A1 (en) 2011-10-13
CA2725833A1 (en) 2002-07-18
ATE508738T1 (de) 2011-05-15
CA2434169A1 (en) 2002-07-18
EP1349531A1 (en) 2003-10-08
US7964216B2 (en) 2011-06-21
JP2004523510A (ja) 2004-08-05
MXPA03006217A (es) 2004-10-15
US20040086562A1 (en) 2004-05-06
WO2002055009A1 (en) 2002-07-18
CA2434169C (en) 2011-03-15
PL362687A1 (en) 2004-11-02
EP1738751B1 (en) 2011-05-11
EP1738751A2 (en) 2007-01-03
JP4633329B2 (ja) 2011-02-16

Similar Documents

Publication Publication Date Title
PL362687A1 (en) Spaced drug delivery system
EP1064000A4 (en) VITAMIN D AND ITS ANALOGS FOR TREATING TUMORS AND OTHER HYPERPROLIFERATIVE DISEASES
JP2006501240A5 (pt)
IL208184A0 (en) Glp-1, and methods for treating diabetes
BRANDRUP Tetrabenacine treatment in persisting dyskinesia caused by psychopharmaca
BR0115392A (pt) Método para o tratamento de uma doença sensìvel a interferona em um animal de sangue quente, método para individualizar as dosagens de uma interferona no tratamento, método para a fabricação de um dispositivo de liberação de efeito terapêutico de longa duração de uma droga ao longo de um perìodo de tempo, e conjunto útil para a ministração de uma quantidade relativamente constante de uma droga
Durand A behavioral/pharmacological intervention for the treatment of severe self-injurious behavior
ES2236551T3 (es) Combinacion de principios activos para el tratamiento medico de toxicomanias.
BR9913746F1 (pt) derivado de piridínio, processo para a preparação do mesmo, uso do mesmo, composição farmacêutica, processo para preparação de uma formulação parenteral, e, métodos de tratamento de um paciente diabético e de prevenção ou de tratamento de doenças causadas por diabetes e por complicações relacionadas com o envelhecimento
WO2009003694A3 (en) Method for treating diseases related to mitochondrial dysfunction
Prasad Efficacy of trazodone as an anti obsessional agent
Hashmat et al. A lethal complication of papaverine-induced priapism
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
WO2005087255A3 (en) Method of optimizing treatment with interferon-tau
BR0311180A (pt) Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos
JP2004503471A5 (pt)
US20090304776A1 (en) Transmucosal delivery of therapeutic agents and methods of use thereof
Schechter Common pain problems in the general pediatric setting
DK1243581T3 (da) Pyridiniumforbindelser til behandling af AGE-relaterede sygdomme
Fu et al. A clinical comparative study on effects of intracavernous injection of sodium nitroprusside and papaverine/phentolamine in erectile dysfunction patients.
US20040192781A1 (en) Method of administration for metoclopramide and pharmaceutical formulation therefor
RU2019174C1 (ru) Способ лечения гиперкинезов у детей
RU2004116492A (ru) Способ профилактики реперфузионных осложнений при турникетной травме
Vasil'ev et al. Effectiveness of pariet (rabeprazole) in the treatment of gastroesophageal reflux disease (at the reflux-esophagitis stage)
EP1861088A1 (en) Medicament and treatment for herpes simplex

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]